Virtual Library
Start Your Search
C. Park
Author of
-
+
P1.06 - Poster Session/ Screening and Early Detection (ID 218)
- Event: WCLC 2015
- Type: Poster
- Track: Screening and Early Detection
- Presentations: 1
- Moderators:
- Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P1.06-029 - Serum Glutathione Peroxidase 3 as a Biomarker of Postoperative Relapse in Patients with Lung Cancer (ID 892)
09:30 - 17:00 | Author(s): C. Park
- Abstract
Background:
Glutathione peroxidase 3 (GPx3) which is an extracellular secretory protein is down regulated in patients with early stage lung cancer. We examined the usefulness of serum GPx3 as a biomarker for monitoring of relapse after surgery.
Methods:
We prospectively collected serial serum samples at baseline, 3 months (3m), 6 months (6m), and 12 months (12m) after operation from the patients who underwent surgery during the year 2013. GPx3 levels were measured three times per sample using the enzyme-linked immunosorbent assay, and the mean values were analyzed by repeated measure analysis of variance.
Results:
A total of 126 (73 adenocarcinoma, 31 squamous cell carcinoma, 22 others) patients were analyzed in this study. Median age of patients was 66 years old (range, 39-80) and 19 (15.4%) out of 123 lung cancer patients were confirmed relapse during the follow-up period of 2 years. In squamous cell carcinoma, the changes of mean serum GPx3 were significantly different between relapse (baseline: 13.3 ± 1.1 μg/mL, 3m: 17.1 ± 4.6 μg/mL, 6m: 14.8 ± 2.7 μg/mL, 12m: 17.9 ± 1.7 μg/mL) and control group (baseline: 10.8 ± 2.3 μg/mL, 3m: 13.4 ± 3.4 μg/mL, 6m: 12.4 ± 2.6 μg/mL, 12m: 13.5 ± 4.7 μg/mL, p=0.043). The changes of mean serum GPx3 levels were not different between two groups in all histology (p=0.258) and adenocarcinoma (p=0.701).
Conclusion:
Postoperative serum GPx3 levels were significantly elevated only in relapsed squamous cell histology, not in adenocarcinoma. More large scaled validation studies are warranted.
-
+
P2.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 234)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/08/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P2.04-089 - Detection of Epidermal Growth Factor Receptor (EGFR) Mutations in Circulating Tumor DNA During EGFR-Tyrosine Kinase Inhibitor Treatment (ID 575)
09:30 - 17:00 | Author(s): C. Park
- Abstract
Background:
Epidermal growth factor receptor (EGFR) mutations are predictive marker of EGFR-tyrosine kinase inhibitor (TKI) therapy. We compared the sensitivity of EGFR mutation detection techniques between tumor tissue and peripheral blood sample in patients with EGFR-TKI treatment.
Methods:
We collected plasma and serum sample before EGFR-TKI and after acquired resistance in 11 patients with EGFR mutations (5 cases of 19 deletion and 5 cases of L858R) from paraffin-embedded tissues using PNAClamp[TM]EGFR Mutation Detection kit. DNA extraction from plasma and serum was performed using the QIAamp MinElute virus spin kit. EGFR mutation analysis for blood was done by pyrosequencing and PANAMutyper[TM]R EGFR kit. The degree of agreement was evaluated by Cohen's kappa value.
Results:
The median EGFR-TKI duration of total 11 (7 male, 4 female) cases was 6 months (range 4-24). The sensitivity of plasma EGFR mutations were 33.3% in pyrosequencing. The sensitivities of PANAMutyper[TM]R were 72.7% in plasma and 45.5% in serum sample. The degree of agreements between tissue and blood sample were better in plasma PANAMutyper[TM]R (k=0.429, p=0.033) and serum PANAMutyper[TM]R (k=0.290, p=0.026) than plasma pyrosequencing (k=0.194, p=0.087). After the development of acquired resistance, plasma EGFR mutations were still detected in 4 cases by PANAMutyper[TM]R. One of them showed 19 deletion and T790M mutation at the same time.
Conclusion:
The sensitivity and the strength of agreement of PANAMutyper[TM]R test were better than pyrosequencing. So this technique can be useful to detect EGFR mutation in peripheral blood.
